Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis
Eva M. Medina‐Rodríguez(Hospital Universitario Doctor Peset), Alfonso Lagares(Universidad Complutense de Madrid), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Ana Bribián(Consejo Superior de Investigaciones Científicas), Carmen Gil(Instituto de Salud Carlos III), Anna Williams(Royal Society of Edinburgh), Jesús Pastor(Hospital Universitario de La Princesa), Amanda Boyd(MRC Centre for Regenerative Medicine)
Cited by 53
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293